FDA launches digital health-focused center of excellence

FDA
The FDA appointed Bakul Patel as its new center’s first director. Patel has helped lead the FDA’s regulatory and scientific efforts on digital health devices since 2010. (Andrew Harnik, Associated Press)

The FDA has launched a new center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments. 

It will also promote strategies for the regulation of health IT services and technologies for studying drugs and devices as well as artificial intelligence and machine learning programs. 

Going forward, the initiative will serve as a coordinating hub within the agency’s Center for Devices and Radiological Health to assist with related regulatory activities and to provide digital health policy expertise to the FDA as a whole.

The agency appointed Bakul Patel, who has helped lead the FDA’s regulatory and scientific efforts covering digital health devices since 2010, as the new center’s first director.

“The establishment of the Digital Health Center of Excellence is part of the planned evolution of the FDA’s digital health program to amplify the digital health work that is already being done and building upon years of work at the agency,” said the FDA’s device center director, Jeff Shuren.

“In the last several years, we have established partnerships internally and externally to coordinate digital health activities and to promote the consistency of regulatory policy while continuing to innovate in our regulatory approaches,” Shuren added.

RELATED: FDA delivers regulatory guidance on AI software and clinical decision-making aids

The FDA plans to hold virtual listening sessions with the digital health industry this fall as the agency continues to build out the center and refine its purview. The center of excellence will also work to build a network of digital health experts to help develop the FDA’s priorities and launch strategic partnerships with stakeholders in the community.

“Today’s announcement marks the next stage in applying a comprehensive approach to digital health technology to realize its full potential to empower consumers to make better-informed decisions about their own health and provide new options for facilitating prevention, early diagnosis of life-threatening diseases, and management of chronic conditions outside of traditional care settings,” FDA Commissioner Stephen Hahn, M.D., said.

Suggested Articles

Novo Nordisk said it is stopping development of NN9828 in combination with Victoza “following an evaluation of the regulatory path forward.”

Bellicum’s shares are being routed after it announced a full house of horrors: poor data, a paused program and slashing the majority of its staff.

C2N Diagnostics launched a blood test that can identify the state of amyloid plaque in the brain, one of the hallmarks of Alzheimer's disease.